Drawing for SKYLINEDX

USPTO serial 79185230

SKYLINEDX

Reviewed by CopyMark Law Group

Status 402
Filing date
Status date
Registration date
—
Examiner
WELLS, KELLEY L
Law office
TMO LAW OFFICE 118- EXAMINING ATTORNEY ASSIGNED

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SKYLINEDX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Molecular diagnostic test reagents; molecular diagnostic test reagents of body substances, such as bone marrow samples, blood samples, and on human or animal tissue; molecular diagnostic test reagents for cancer; molecular diagnostic test reagents, inter alia on the basis of microarray technology (next generation) sequencing technology; reagents for use in medical genetic testing; reagents for use in medical genetic testing for the measurement of the gene expression profile, reagents for use in medical genetic testing for the measurement of gene aberrations and mutations, clinical multiplex (research) testing, inter alia, for the determination of the genetic sub-type of a patient; prognostic test reagents; predictive test reagents, in search of the effectiveness of a medical treatment and/or to select the medical treatment; reagents and other supplies for diagnostic testing; chemical preparations, for medical purposes, for the testing of blood and human or animal tissue, including cancer cellsSECTION 70 - CANCELLED—
009Software; software and algorithms for performing diagnostic tests for medical purposes; software for generating and reading out of the (complex) genetic properties of the patient sample; software for interpreting the obtained raw genetic information for inter alia laboratory users, molecular biologists, pathologists, physicians and patients, comprehensive and relevant information (such as the presence of a genetic aberration, mutation, or gene expression profile, genetic subtype of the disease or clinical consequence thereof as well as poor or good prognosis, whether or not in combination with a specific treatment); validated software for secure IT infrastructures for clinical purposes; databases containing anonymous genetic data of patients from clinical studies for comparison with the genetic outcome of patients samplesSECTION 70 - CANCELLED—
035Compilation of medical and veterinary informationSECTION 70 - CANCELLED—
042Scientific research for the benefit of the development of molecular diagnostic tests; developing software for performing diagnostic tests for medical purposes, as well as developing software and algorithms and / or databases for translation (reading), analyzing and interpreting test results; molecular diagnostic analysis; investigation and analysis of body substances and molecular diagnostic test scores for the purpose of the development of new biomarkers, testing, and (corresponding) methods of treatment; leasing of computer software for reading test results; development and testing services for the certification of quality or standards of (molecular) diagnostic testsSECTION 70 - CANCELLED—
044Medical analysis services; analysis of medical and veterinary test scores and data for others; medical and veterinary information services provided via the internetSECTION 70 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 7, 2026DETHDEATH OF INTERNATIONAL REGISTRATION—
Aug 6, 2022ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Nov 24, 2017FINTFINAL DECISION TRANSACTION PROCESSED BY IB—
Nov 9, 2017FICSFINAL DISPOSITION NOTICE SENT TO IB—
Nov 9, 2017FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Sep 15, 2017OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Aug 30, 2017OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Aug 30, 2017OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Nov 10, 2016MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Nov 9, 2016ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
May 14, 2016RFNTREFUSAL PROCESSED BY IB—
Apr 1, 2016MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 31, 2016RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 31, 2016RFRRREFUSAL PROCESSED BY MPU—
Mar 30, 2016RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 29, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 28, 2016DOCKASSIGNED TO EXAMINER—
Mar 28, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 24, 2016REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance